Many San Diego doctors are taking their patients off of Invokana, a widely used diabetes drug, after a large industry-sponsored trial found it doubled the risk of lower limb amputations compared with those taking a placebo.
[one_half][box type=”shadow this-matters”]With 23.1 million people in the U.S. diagnosed with diabetes, many of them are taking newer drugs to control glucose. But new research involving one of those drugs, Invokana, shows a doubled rate of leg, foot and toe amputations.[/box]
Patients are being switched to other medications even though the study’s authors say the drug’s benefits — a reduced risk of cardiovascular events including death, non-fatal heart attacks and non-fatal strokes — outweigh its risk of amputations.
The drug is prescribed for people with Type 2 diabetes. The patients in the trial were already at high risk for heart disease and other diabetes complications including amputations.
While a number of physicians interviewed said they still prescribe the drug to lower their patients’ glucose levels, attitudes among others began to change after the U.S. Food and Drug Administration on May 16 issued what’s called a black box warning about amputations.
It urges patients taking canagliflozin, sold under the brand name Invokana, Invokamet and Invokamet XR, to contact their doctors “right away” if they notice pain or tenderness, sores, ulcers or infections in their legs or feet. About half of the amputations occurring among patients in the trial were of toes, while the rest were across the foot, at the ankle, below the knee and above the knee.
The FDA warning suggests physicians should consider factors that predispose patients to amputations, such as prior amputations, peripheral vascular disease, neuropathy and diabetic foot ulcers, before prescribing the drug. Physicians should also monitor patients for ulcers, sores, pain or tenderness “and discontinue canagliflozin if these complications occur,” the FDA said.
Physicians in the Sharp HealthCare system have begun switching patients to other drugs in a “process that has been underway since the FDA warning came out,” spokesman John Cihomsky said in an email. The focus is on patients with key risk factors, such as prior amputations, he said.
[box type=”white post-form”]
Oops! We could not locate your form.
[/box]The trial also found a small increase in diabetic ketoacidosis, a potentially fatal condition if left untreated, in study participants taking canagliflozin compared with participants who took a placebo. Canagliflozin is in the same class of medication as two other drugs, Jardiance and Farxiga. The FDA in 2015 also issued a warning about ketoacidosis in that class of medications.
The Scripps Health system’s hospital pharmacy and therapeutics committee recently voted to keep canagliflozin off of its list of drugs it uses for hospitalized patients, committee chair Dr. Valerie Norton said in an email.
Norton said that in her role as an emergency room physician at Scripps Mercy Hospital she personally saw a very sick patient with diabetic ketoacidosis, which was thought to be a side effect of taking Invokamet.
Dr. Paul Speckart, a Bankers Hill endocrinologist on staff at Scripps Mercy, said his five-physician practice has removed all canagliflozin samples from its shelves and is no longer prescribing it. For the few patients who have been on the drug, he said, they’re writing prescriptions for Farxiga, known chemically as dapagliflozin.
Lower limb amputations are a known complication in people with diabetes. According to the Centers for Disease Control and Prevention, 108,000 hospital discharges occurred in 2014 among patients with diabetes who had amputation surgery, or a rate of 5 per 1,000 diabetes patients.
The research, named CANVAS for the Canagliflozin Cardiovascular Assessment Study, began in 2009. When the third phase of the research showed benefits in lowering glucose in patients with diabetes, the FDA approved Invokana in 2013. In the recent longer look, however, CANVAS revealed a doubled amputation risk that was a surprise.
Many patients could be affected
According to one company that collects drug sales information, SymphonyHealth, 4.5 million Invokana prescriptions were filled in 2016 in the United States, with sales of $2.33 billion, making it 48th in dollar sales of all U.S. drugs that year.
The drug is sold by Janssen, a division of Johnson & Johnson, which financed the research.
Asked to respond to concerns about the drug’s doubled amputation risk, Janssen spokeswoman Jessica Castles Smith said in an email that the safety of Invokana has been demonstrated by 14 million prescriptions and controlled studies in more than 24,000 patients, and that the increased risk of amputations was 0.3 in 100 patients treated for a year or from 0.3 to 0.6.
“We are confident in the proven cardiovascular and renal safety profile of Invokana (canagliflozin) and the benefits it can bring to people living with type 2 diabetes,” she said. The drug “significantly reduced the combined risk of cardiovascular death, nonfatal myocardial infarction (heart attack) and non-fatal stroke across a broad patient population.”
Health systems taking action
Kaiser Permanente in California has an “extremely low” volume of Invokana prescriptions written for its patients, spokeswoman Jennifer Dailard said. Kaiser is giving its physicians lists of patients who have received the drug so they can be closely monitored and suggesting the drug be discontinued for patients with certain risk factors, such as foot ulcers.
Dr. Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, said about half of his heart disease patients also have diabetes so he prescribes diabetes drugs as well. But now, he said, he is “uncomfortable prescribing (Invokana) in view of the amputation risk.” He calculated that one patient out of every 69 people who takes canagliflozin for five years will have a drug-related amputation.
That’s correct, said Dr. Kenneth Mahaffey, director of the Stanford Center for Clinical Research, one of the authors of the study findings, published June 12 in the New England Journal of Medicine.
“There absolutely is an increased risk of amputations with canagliflozin,” according to that trial, Mahaffey said. Even so, he said, “We have to put the risk of amputations in perspective with the clear benefits we’re seeing.”
In the CANVAS trial, Mahaffey noted that for every 1,000 patients treated for five years, 23 fewer patients had a cardiovascular death, a heart attack or stroke, 16 fewer patients were hospitalized for heart failure, 17 fewer patients required dialysis or required a transplant, compared with those treated with a placebo. For every 1,000 patients in the study followed for five years, 15 patients suffered an amputation, he said.
“Even though amputation was a significant event for patients … both physically and psychologically, 10 of the 15 suffered toe or metatarsal (across the foot) amputations and only five had above the ankle amputations,” he said.
Mahaffey said the study did not give any hints why amputations are only being seen now, four years after the trials that led to the FDA’s approval of Invokana.
Many doctors are now expected to watch if other drugs in the the same class — specifically the newer drugs Jardiance (empagliflozin) and Farxiga (dapagliflozin) — have similar amputation risks, although none has been shown to date.
Mahaffey said he is considering switching his patients to another drug if they have had a prior amputation or peripheral vascular disease.
What would be the next drug to use? “That’s a great question,” Mahaffey said. “I probably would not use another (drug in that class) until we have more data.”
Cardiac benefits questioned
Dr. John Buse, a diabetes researcher and chief of endocrinology at the University of North Carolina who was an investigator for the Invokana clinical trial, vociferously questioned the methodology that concluded the drug prevented major cardiac events.
He said the heart attacks noted in the study were relatively minor and most not life-threatening.
That negates the study’s findings of cardiac benefit, Buse said, predicting the FDA would never approve the drug to prevent cardiovascular events based on current data.
The doubled amputation risk should be taken much more seriously, he emphasized. “Losing a toe, or a big toe, is a big deal. You’d have to think about that two or three times before you’d accept a big toe amputation in lieu of a small heart attack,” Buse said.
Doctors caution against panicking
But several doctors interviewed said taking patients off the drug en masse is an overreaction that could harm patients. They asked whether a person with diabetes would rather have a heart attack or a toe amputation.
“There’s a little bit of inappropriate panic going on right now,” among doctors treating diabetes, said Dr. Steven Edelman, a diabetes researcher at UC San Diego Medical Center and the Veterans Affairs Medical Center.
He sees the amputation issue as overblown. “The risk is still pretty darn small, with no real explanation for the mechanism” that appears to be driving a higher rate of amputations, he said.
Edelman, founder of the Solana Beach non-profit “Taking Control of Your Diabetes,” said he “respects any physician who looks at that data and says, hey, there’s other drugs on the market. … I’m going to switch.” He is continuing to prescribe Invokana.
“Bladder cancer and bone fractures have been seen with other drugs in the same class but without the hysteria,” he said.
Edelman worries that some patients may be scared away from a drug they could benefit from, stop taking it and not replace it. Then their disease could get worse, he said.
Dr. Georges Argoud, an endocrinologist with privileges in the Sharp and Scripps health care systems, also still prescribes Invokana because of the benefits.
“I think it’s a little bit extreme to all of a sudden decide you’re not going to use this medication,” he said.
“It’s not very often that we see amputations anymore because we’re doing a pretty good job of educating patients, physicians and emergency rooms, and being very aggressive with the management of foot ulcers. Podiatrists are doing a great job,” Argoud said.
In his three-physician practice, he said, he can’t remember the last time anyone saw a patient who had to have an amputation.
He and others noted that no trials have been done that compared Invokana head-to-head with other drugs that treat diabetes, but it’s something he said should be closely monitored by doctors and patients.
The amputation warning also did not dissuade CVS Health, the largest pharmacy benefit manager in the nation covering 90 million insured patients, to add Invokana to its standard list of covered drugs, or formulary, starting in January, spokeswoman Christine Cramer said. But CVS is removing Jardiance.
“Many widely used drugs have black box warnings,” Cramer said, adding that the increased risk of amputations in Invokana “was found in only one of 12 studies of the drug, and data regarding amputations have not been collected systematically in trials of Jardiance.”
Public Citizen says ‘do not use’
For Michael Carome, director of Public Citizen’s Health Research Group, the amputation finding was not a surprise. His group designated Invokana as a “do-not-use” drug in February 2014, shortly after it was approved. Its Worst Pills Best Pills newsletter said “canagliflozin has not been shown to offer any unique clinical benefits in comparison to several older, safer diabetes drugs. Yet it does pose serious risks that outweigh any of its benefits.”
Those risks included kidney injury and serious urinary tract fungal infections.
The recent amputation issue “is a significant safety finding, and for us adds to our position that the drug should be avoided,” Carome said in an interview.
Trials done before the drug was approved, he said, “were relatively short, and the main outcome they’re looking for is the effect on glucose levels.”
The Veterans Health Administration does not keep canagliflozin on its formulary, and said in an email that if doctors want to prescribe it, “that’s a decision that is made jointly by the patient and his/her care team based on the clinical needs of the patient after assessing the risks versus benefits.”
Health plans weigh drug’s cost
Dr. Jeffrey Sandler, a Hillcrest diabetes specialist affiliated with Scripps Mercy, suggested many decisions to discontinue the drug have to do with how much health plans and managed care groups — which have to cover the costs of patient care out of a flat per-patient rate — receive for each enrollee.
A 30-day drug supply can cost as much as $585 for a consumer without a health plan rate, discount or coupon.
“They’re very expensive drugs, so many managed care groups really don’t want to use it,” Sandler said. “On the other hand, endocrinologists and some internists do want to use it.
“For a medical group like Sharp, which oversees not just Sharp health insurance plans but Rees-Stealy (medical groups), you have to take it with a grain of salt.”
Meanwhile, attorneys are circulating ads to recruit for class-action lawsuits patients who have used Invokana if they have had leg, foot or toe amputations or ketoacidosis.
Argoud said some of his patients have become afraid of Invokana and other drugs whose harmful side effects are the subject of law firm client recruitment.
He tries to reassure them by saying: “Are you going to make decisions about your health care by looking at ads on TV, or are you going to listen to your endocrinologist, someone who has read the data and is in tune with the literature?”
With Invokana, he said, “You have a pattern of benefits that’s amazing. None of the other drugs have demonstrated in such well-done trials to reduce cardiovascular disease.” It also comes with no weight gain and no hypoglycemia, like with many of the other drugs, Argoud said.
Mahaffey said many more studies are underway, as well as more detailed analysis of the CANVAS trials. “Hopefully, we’ll have presentations and publications (about this) in the near future,” he said.
More in the series …
[divider style=”4″]
[one_third]
[two_third_last]Medicare to pay $450 to help seniors lose weight, avoid diabetes
June 29, 2017
Some 86 million Americans live with prediabetes, which can progress to diabetes, a costly and debilitating disease. A new program can help people lose weight, a proven way to reduce the risk of getting the disease.[/two_third_last]
[divider style=”4″]
[one_third]
[two_third_last]Spending on diabetes drugs is ‘skyrocketing’
July 5, 2017
The largesse of a the drug industry related to diabetes is skyrocketing by any measure: dollar cost per unit, the number of people purchasing them and the number of prescriptions sold.[/two_third_last]
[divider style=”4″]
[one_third]
[two_third_last]Medicare boosts incentives to promote weight loss, prevent diabetes
July 17, 2017
Participating providers — from hospital systems and physician groups to wellness centers, supermarket chains and even churches — could receive up to $785 for each participant who loses 5 percent of their body weight.[/two_third_last]
[divider style=”4″]
[one_third]
[two_third_last]Doctors debate danger of popular diabetes drug after FDA amputation warning
August 31, 2017
Many San Diego doctors are taking their patients off of Invokana, a widely used diabetes drug, after a large industry-sponsored trial found it doubled the risk of lower limb amputations compared with those taking a placebo.[/two_third_last]
[divider style=”4″]
[one_third]
[two_third_last]Diabetes-related amputations up significantly in California — and San Diego
Sept. 20, 2017
Clinicians are amputating more toes, legs, ankles and feet of patients with diabetes in California — and San Diego County in particular — in a “shocking” trend that has mystified diabetes experts here and across the country.[/two_third_last]
[divider style=”4″]
[one_third]
[two_third_last]Diabetes-related amputations: How we crunched the data
Sept. 20, 2017
To identify the increase in diabetes-related amputations in California, inewsource analyzed data from the California Office of Statewide Health Planning and Development, the agency that collects information about the care provided to patients discharged from California hospitals.[/two_third_last]
- Editorial Standards Page
- Ethics Policy
- Diversity Statement
- Diversity Staffing Report
- Corrections Policy
- Ownership Structure, Funding
- Founding Date
- Masthead
- Mission Statement with Coverage Priorities
- Fact-checking Standards
- Unnamed Sources Policy
Editorial Standards Page
- Our Mission
- Ethics Policy
- Diversity
- Ownership Structure, Funding and Grants
- Financial Documents
- Fact-checking and Verification Standards
- Unnamed Sources
- Corrections and Clarifications
- Actionable Feedback and Newsroom Contacts
- Masthead
- Byline Policy
- The Trust Project
- Privacy Policy
Our Mission
inewsource is a nonprofit, nonpartisan newsroom dedicated to improving lives in the San Diego region and beyond through impactful, data-based investigative and accountability journalism.
Our Vision
Betrayals of the public trust are revealed and rectified, wrongdoing is deterred, and inequities are illuminated thanks to inewsource’s deep, dogged, fact-based reporting.
Our Values
Truth: Above all else, we value the importance of a free and credible press. Truth is the cornerstone of democracy and the core value for inewsource.
Transparency: We build trust with our readers by adhering to the highest standards and ethics, and to reporting with facts, precision and context.
Collaboration: Our newsroom prioritizes collaboration over competition. We regularly partner with media outlets on reporting projects and to share content.
Community: Our reporting serves the San Diego region, and we strive to build relationships with our audience by getting out into the community to listen and engage.
Ethics Policy
inewsource will conduct its business with the highest standards of decency, fairness and accuracy. These standards shall apply equally to inewsource employees, freelancers and all others engaged in gathering information on behalf of inewsource. All receive a copy of these ethical standards.
In the course of our reporting, we will consistently:
● Identify our organization and ourselves fully and avoid false representations of any kind to any source.
● Obtain consent from all parties before electronically recording any interview or conversation except in extraordinary cases authorized by the Managing Editor and Editor. If a source refuses to be taped, that must be honored; no recordings are to be made without consent.
● Respect the individual’s right to privacy. inewsource will never manipulate or barter private, personal, health, financial or other extraneous information in the course of preparing its reports.
● Any source we describe or write about in any significant manner must be contacted. The employee should document all efforts to contact the source, and if unsuccessful, should summarize these efforts at contact in the body of his/her writing.
In addition, inewsource follows the Code of Ethics of the Society of Professional Journalists. The latest version, revised in 2014, can be found here.
Editorial Independence Policy
We subscribe to standards of editorial independence adopted by the Institute for Nonprofit News (INN) as follows:
Our organization retains full authority over editorial content to protect the best journalistic and business interests of our organization. We will maintain a firewall between news coverage decisions and sources of all revenue. Acceptance of financial support does not constitute implied or actual endorsement of donors or their products, services or opinions.
We accept gifts, grants and sponsorships from individuals and organizations for the general support of our activities, but our news judgments are made independently and not on the basis of donor support. Our organization also may consider donations to support the coverage of particular topics, but our organization maintains editorial control of the coverage. We will cede no right of review or influence of editorial content, nor of unauthorized distribution of editorial content.
Our organization will make public all donors who give a total of $1,000 or more. We will accept anonymous donations for general support only if it is clear that sufficient safeguards have been put into place that the expenditure of that donation is made independently by our organization and in compliance with INN’s Membership Standards.
Diversity
Diverse Voices
Inclusiveness is at the heart of thinking and acting as journalists, and it supports the educational mandate of inewsource. Race, class, generation, gender, sexual orientation, ability, and geography all affect point of view. inewsource believes that reflecting societal differences in reporting leads to better, more nuanced stories and a better-informed community.
inewsource is committed to employment equity and diversity.
Diverse Staffing Report
Below is a breakdown of staffing data at inewsource. We determine the composition of our staff by asking them to self-identify. It is based on a newsroom of 11 and a total staff of 15 as of August 2020. Percentages are based on 15 total survey responses. The numbers include full-time and part-time staff, full-time fellows and full-time and part-time interns.
| All Staff Percentages are based on 15 total survey responses. The numbers include full-time and part-time staff, full-time fellows and full-time and part-time interns. | Newsroom Percentages are based on 15 completed survey responses to this question. | Business Percentages are based on 15 completed survey responses to this question. | |||
| Gender Identity | Gender Identity | Gender Identity | |||
| Women | 80% | Women | 82% | Women | 75% |
| Men | 20% | Men | 18% | Men | 25% |
| Sexual Orientation | Sexual Orientation | Sexual Orientation | |||
| Straight | 87% | Straight | 82% | Straight | 100% |
| LGBTQ-identifying | 7% | LGBTQ-identifying | 7% | ||
| Not specified | 7% | Not specified | 7% | ||
| Speak a language beyond English at home | 33% | Speak a language beyond English at home | 18% | Speak a language beyond English at home | 75% |
| Race/Ethnicity | Race/Ethnicity | Race/Ethnicity | |||
| White | 67% | White | 73% | White | 50% |
| Hispanic or Latinx | 20% | Two or more races | 18% | Hispanic or Latinx | 50% |
| Two or more races | 13% | Hispanic or Latinx | 9% | ||
| Age | Age | Age | |||
| 20-29 | 40% | 20-29 | 45% | 20-29 | 25% |
| 30-39 | 47% | 30-39 | 45% | 30-39 | 50% |
| 60 or older | 13% | 60 or older | 9% | 60 or older | 25% |
* The percentages in the charts have been rounded and may not add up to 100.
Ownership Structure, Funding and Grants
inewsource is a nonprofit organization, whose legal name is Investigative Newsource. It does business as inewsource. The business was incorporated on Aug. 4, 2009 in the state of California. Tax-exempt status as a 501c3 was granted by the IRS on Sept. 15, 2010. inewsource is funded primarily by individual contributions and foundation grants. We are guided by a board of directors.
Editorial independence: Journalists employed by inewsource take no editorial direction from donors whose contributions may support the organization. inewsource will not hesitate to report on its donors when events warrant. Our Editorial Independence Policy details the firewall between journalism and revenue.
To be transparent with the public, inewsource lists its donors on its website. In cases where a donor is the subject of an inewsource story, additional disclosure will be made.
Financial Documents
We do our due diligence to earn your trust in our reporting, as well as in our governance and financial sustainability. All of our financial documents are made available to view so that our supporters can trust we are sound stewards of your philanthropy. Review our IRS Form 990s, audited financial statements and annual reports:
Tax Returns
Financial Statements
Annual Reports
Fact-checking and Verification Standards
Transparency is one of our core values. Today, there is a need to build trust with our audience because new media and ways of communicating spread lies and slanted news faster than “real” news. At the same time, this era of new technologies makes it easier than ever for news organizations to be transparent. People don’t just have to believe us, they can investigate our investigations with our source materials.
Transparency is key to building credibility.
inewsource reporters have primary responsibility for reporting, writing, and fact-checking their stories. But before a story is published, the reporter reviews all facts and sources with an editor or another reporter. Facts must be traced to a primary source.
In addition, we “transparify” certain investigative stories. This process involves publishing a version of the web story with hyperlinks to all the story’s facts. This is proof that all facts have been documented with primary evidence. We do this to build trust with our readers and to be as transparent as we hope the public figures and institutions that we hold accountable will be.
Unnamed Sources
Not all sources are created equal. Some sources cannot speak authoritatively, provide proper analysis or speak specifically to every inquiry placed before them. To maintain the integrity of our reporting, inewsource reporters must select sources who can speak with validity to the topic at hand, and avoid presenting unqualified or underqualified sources as experts.
If an interviewed source has a conflict of interest, or whose qualifications may be tangential or limited, reporters will note that within the context of the story.
It is incumbent upon reporters to fully background their sources to uncover conflicts of interest or slant prior to using them in a story.
Unless discussed prior to an interview, all subjects talking to inewsource journalists are on the record. Specifically, the source is identified by name and title, and their exact or paraphrased words are attributed to them for publication. If journalists speak with sources who are not politicians, public figures or those not commonly interviewed by journalists, staff should explain clearly that information discussed will be on the record and for publication.
There are times, however, when information may be critical for a story but cannot be found or verified by other means. For example, a source may be able to confirm specific information about a series of events they may have witnessed, but have legitimate concerns about using their name or title. The repercussions to the source could be legal, job-related retribution or personal safety. The source and journalist must discuss these potential dangers and terms of use should be agreed upon by both parties.
If inewsource publishes information from an anonymous source, inewsource will explain to readers, in as much detail as possible, why we agreed to anonymity.
Corrections and Clarifications
inewsource strives for accuracy in everything we do, which is why we are committed to fact checking our content. But sometimes we make errors. When that happens, we correct them. We also clarify stories when something we’ve written is confusing or could be misinterpreted.
We endeavor to always be transparent about our commitment to correcting errors and clarifying misperceptions. When staffers see, hear or read about a possible issue with the accuracy of any inewsource content, they are expected to bring it to the attention of an editor and the web producer so it can be evaluated to determine how to proceed.
Including the web producer is key because inewsource is a multimedia news organization and shares its content with multiple partners on multiple platforms. The web producer must alert these partners about corrections and clarifications.
Corrections and clarifications should be included at the bottom of stories and dated.
Actionable Feedback and Newsroom Contacts
Our audiences know the region we cover and have a stake in maintaining and improving the quality of life in San Diego and Imperial counties. We know your knowledge and insights can help shape what we cover and how we cover it. We invite your comments and complaints on news stories, suggestions for issues to cover or sources to consult. We rely on you to tell us when we get it right and when we need to keep pushing.
Your comments, questions and suggestions can be sent to the team as a whole at contact@inewsource.org or you can contact a specific member of our staff.
Masthead
CEO, Editor and Founder: Lorie Hearn, loriehearn@inewsource.org
Lorie Hearn is the chief executive officer, editor and founder of inewsource. She founded inewsource in the summer of 2009, following a successful reporting and editing career in newspapers. She retired from The San Diego Union-Tribune, where she had been a reporter, Metro Editor and finally the senior editor for Metro and Watchdog Journalism. In addition to department oversight, Hearn personally managed a four-person watchdog team, composed of two data specialists and two investigative reporters. Hearn was a Nieman Foundation fellow at Harvard University in 1994-95. She focused on juvenile justice and drug control policy, a natural course to follow her years as a courts and legal affairs reporter at the San Diego Union and then the Union-Tribune.
Hearn became Metro Editor in 1999 and oversaw regional and city news coverage, which included the city of San Diego’s financial debacle and near bankruptcy. Reporters and editors on Metro during her tenure were part of the Pulitzer Prize-winning stories that exposed Congressman Randy “Duke” Cunningham and led to his imprisonment.
Hearn began her journalism career as a reporter for the Bucks County Courier Times, a small daily outside of Philadelphia, shortly after graduating from the University of Delaware. During the decades following, she moved through countless beats at five newspapers on both coasts.
High-profile coverage included the historic state Supreme Court election in 1986, when three sitting justices were ousted from the bench, and the 1992 execution of Robert Alton Harris. That gas chamber execution was the first time the death penalty was carried out in California in 25 years.
In her nine years as Metro Editor at the Union-Tribune, Hearn made watchdog reporting a priority. Her reporters produced award-winning investigations covering large and small local governments. The depth and breadth of their public service work was most evident in coverage of the wildfires of 2003 and then 2007, when more than half a million people were evacuated from their homes.
Managing Editor: Laura Wingard, laurawingard@inewsource.org
Laura Wingard is the managing editor at inewsource. She has been an editor in San Diego since 2002, working at The San Diego Union-Tribune, KPBS and now inewsource. At the Union-Tribune, she served in a variety of roles including as enterprise editor, government editor, public safety and legal affairs editor, and metro editor. She directed the newspaper’s award-winning coverage of the October 2007 wildfires and the 2010 disappearance of Poway teenager Chelsea King. She also oversaw reporting on San Diego’s pension crisis.
For two years, Wingard was news and digital editor at KPBS, overseeing a team of four multimedia reporters and two web producers. She also was the KPBS liaison with inewsource and collaborated with inewsource chief executive officer and editor Lorie Hearn on investigative work by both news organizations.
Wingard also worked at the Las Vegas Review-Journal as the city editor and as an award-winning reporter covering the environment and politics. She also was the assistant managing editor for metro at The Press-Enterprise in Riverside. She earned her bachelor’s degree at California State University, Fullerton, with a double major in communications/journalism and political science.
Assistant Editor and Senior Reporter: Brad Racino, bradracino@inewsource.org
Brad Racino is the assistant editor and a senior reporter at inewsource. He has produced investigations for print, radio and TV on topics including political corruption, transportation, health, maritime, education and nonprofits.
His cross-platform reporting for inewsource has earned more than 50 awards since 2012, including back-to-back national medals from Investigative Reporters and Editors, two national Edward R. Murrow awards, a Meyer “Mike” Berger award from New York City’s Columbia Journalism School, the Sol Price Award for Responsible Journalism, San Diego SPJ’s First Amendment Award, and a national Emmy nomination.
In 2017, Racino was selected by the Institute for Nonprofit News as one of 10 “Emerging Leaders” in U.S. nonprofit journalism.
Racino has worked as a reporter and database analyst for News21; as a photographer, videographer and reporter for the Columbia Missourian; as a project coordinator for the National Freedom of Information Coalition and as a videographer and editor for Verizon Fios1 TV in New York. He received his master’s degree in journalism from the University of Missouri in 2012.
Byline Policy
Most of our articles carry a byline to identify the author. In some cases, inewsource will use a brand byline such as “Staff” or “inewsource” for internal or editorial information about the newsroom. In these instances, inewsource‘s Editor and Managing Editor are responsible for content that uses a brand byline.
The Trust Project
inewsource is proud to be a member of The Trust Project and support efforts to increase transparency in journalism by displaying the 8 Trust Indicators on our stories. We launched the Trust Indicators on Sep. 16, 2020.
Privacy Policy
inewsource has prepared this Privacy Policy to explain how we collect, use, protect, and share information when you use our inewsource.org website (the “Site“) or when you use any of our services (the “Services“).
By using the Site or Services you consent to this Privacy Policy.
Log Data
Like many site operators, we collect information that your browser sends whenever you visit our site (“Log Data”).
This Log Data may include information such as your computer’s Internet Protocol (“IP”) address, browser type, browser version, the pages of our site that you visit, the time and date of your visit, the time spent on those pages and other statistics.
Cookies
Cookies are files with small amount of data, which may include an anonymous unique identifier. Cookies are sent to your browser from a web site and stored on your computer or mobile device.
Like many sites, we use “cookies” to collect information. You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our site.
Certain pages on our site may set other third party cookies. For example, we may embed content, such as videos, from another site that sets a cookie. While we try to minimize these third party cookies, we can’t always control what cookies this third party content sets.
Additionally, we may use third party services — such as those that provide social media conveniences, measure traffic, send newsletters and facilitate donations — that may place cookies on your computer. We don’t have any way of knowing how such services handle the resulting data internally. inewsource makes no claim, nor takes liability for the insecure submission of information via these applications.
Here are the services whose cookies you can find on inewsource.org:
- Sharing buttons for Facebook and Twitter. These use the standard scripts provided by each company.
- Google Analytics, which we use to measure site traffic. Google Analytics gathers certain non-personally identifying information over time, such as your IP address, browser type, internet service provider, referring and exit pages, time stamp, and similar data. We also use Facebook Pixel to measure, optimize and build audiences for advertising campaigns served on Facebook. In particular it enables us to see how our users move between devices when accessing our website and Facebook, to ensure that our Facebook advertising is seen by our users most likely to be interested in such advertising by analyzing which content a user has viewed and interacted with on our website.
- Stripe, which allows us to accept donations through our website.
- Salesforce to manage newsletter subscriber, donor, and other identifiable user data.
- Mailchimp, to manage newsletter distributions. We collect your email address if you choose to subscribe to one of our email newsletters or email news alerts. Other optional information that you enter when subscribing – such as your first and last names or city are simply so that we can deliver more personalized email newsletters. We DO NOT sell, rent or market your information to any other parties. We retain your information only as long as necessary to provide your service. When we send emails, it collects some data about which users open the emails and which links are clicked. We use this information to optimize our email newsletters and, as aggregate information, to explain what percentage of our users open and interact with our newsletters.
Personal Data
We only collect personally identifiable information such as your name and email address when you sign up for a newsletter, donate to our organization, or otherwise submit it to us voluntarily. We do not share your personal data with any third parties other than some common service providers, whose products use your information to help us improve our site, deliver newsletters, or allow us to offer donation opportunities.
inewsource limits access to all user data for the purposes of newsletter, fundraising, and customer service only. User data is not sold to or otherwise shared with anyone not working with or for the inewsource.
You may unsubscribe or opt-out of our email and mail communications at any time by hitting the “unsubscribe” button in any email you receive from inewsource, or by emailing us at contact@inewsource.org or calling us at 619-594-5100.
Donor Information
The identities of all donors will be listed on our website. inewsource does not share, trade, sell, or otherwise release donors’ personal information to any third parties.
Refunds
If you encounter errors when donating on the website, please contact us at members@inewsource.org. For example, if you submit a donation for an incorrect amount or make a duplicate transaction please email us immediately so we can reverse the charges.
Cancellation of Recurring Donations
You can cancel your monthly recurring donations free of charge by notifying us at members@inewsource.org.
Links to Other Websites
Our site may contain links to documents, resources or other websites that we think may be of interest to you. We have no control over these other sites or their content. You should be aware when you leave our site for another, and remember that other sites are governed by their own user agreements and privacy policies, which should be available to you to read.
Disclaimers and Limitation of Liability
Although we take reasonable steps to prevent the introduction of viruses, worms, “Trojan Horses” or other destructive materials to our site, we do not guarantee or warrant that our site or materials that may be downloaded from our site are free from such destructive features. We are not liable for any damages or harm attributable to such features. We are not liable for any claim, loss or injust based on errors, omissions, interruptions or other inaccuracies on our site, nor for any claim, loss or injust that results from your use of this site or your breach of any provision of this User Agreement.
Contact Us
If there are any questions regarding this privacy policy, please contact us at contact@inewsource.org or call us at 619-594-5100.